Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Realgar-Indigo Naturalis Formula（RIF） Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study

NCT07075250 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT07075250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07075250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Realgar-Indigo Naturalis Formula（RIF） Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study
Lead sponsor
Peking University People's Hospital
Phase
Phase 4
Overall status
Not yet recruiting
Start date
September 1, 2025
Completion date
December 31, 2029
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-resistant ovarian cancer (proc)